Community/Retail

CagriSema is a subcutaneous injectable combination of cagrilintide and semaglutide that is currently in phase 3 trials.

Participants who completed the curriculum had answered 82% of the post-test correctly.

Glucagon-like peptide-1 agonists have increasingly showed potential for treating liver fibrosis in patients, which disproportionately affects those who are overweight or have obesity.

Automation can enhance safety and efficiency and allow staff to concentrate on higher-value tasks as direct patient care roles expand.

Vitamin K2 displayed a marked reduction in cramp frequency compared to a placebo.

Pharmacists should be aware of current discussions, attempted fixes, and expected length of drug shortages.

Reasons for supporting the lowering of the age-based pneumococcal vaccine recommendation included the likelihood it would increase vaccination rates in multiple age groups and demographics.

Brivudine is more effective in treating herpes zoster and does not increase the risk of adverse reactions.

The demanding nature of pharmacy programs often leaves little time for self-care, social activities, or hobbies, leading to an imbalance that can foster burnout.

Though both vaccines remain effective at preventing severe illness, Moderna’s mRNA-1273.222 vaccine was found to be significantly more effective among adults with underlying medical conditions.

The study found that this patient population was about 25% more likely to have serious mental health issues after childbirth.

Tripp Logan, PharmD, reflects on being named Independent Pharmacist of the Year from the National Community Pharmacists Association.

RSV vaccines were 80% effective in preventing hospitalization, ICU admission, and death among adults aged 60 years and older.

Children with certain atopic conditions, including asthma and common food allergies, were observed to have a higher risk of developing the chronic disorder.

Lerodalcibep is a novel, third-generation, anti-PCSK9 therapy small binding protein.

Pharmacists, who play a crucial role at the intersection of prescribing and dispensing, are well-positioned to influence these disparities.

In addition to GLP-1s, dual GLP-1 and GIP agonists, intestinal lipase inhibitors, sympathomimetics, and other agents can help patients lose weight.

Among this population, about 80% had not previously been diagnosed with asthma and over 30% were not using any asthma medications.

New technology and innovation may help turn the corner on antibiotic resistance.

Brian Anderson, PharmD, RPh provides important considerations for pharmacists regarding patient use of benzodiazepines.

Clesrovimab reduced RSV-associated hospitalizations and RSV-associated lower respiratory infection hospitalizations by more than 84% and 90% in preterm and full-term infants, respectively.

For up to 6 years, cognitive remediation and transcranial direct current stimulation slowed cognitive decline associated with major depressive disorder in remission and mild cognitive impairment.

The authors believe that improvements can be made to overlook the motherhood penalty and its associated pay gaps as well as changes to address workforce burnout.

Trent Thiede, PharmD, president of Pharmacy Audit Assistance Service (PAAS) International, discussed how pharmacy teams can remain prepared for audits from pharmacy benefit managers (PBMs).

Educating the public about the dangers of self-medication and the importance of finishing prescribed antibiotic courses plays a crucial role

Kristi Veis discusses the importance of flu vaccinations and the role of pharmacists in administering them.

The results found that women, non-binary, and sexual minority students are at the highest risk.

Erin Rexroth, associate director of marketing for NCPA, discussed how pharmacies can utilize marketing strategies to drive awareness and patient engagement.

About 41% and 30% of patients with chronic spontaneous urticaria (CSU), respectively, achieved well-controlled disease status and complete response when treated with dupilumab.

The approval comes after the phase 3 clinical trials MVOR-1 (NCT05296629) and MVOR-2 (NCT05343455).